Deutsche Tageszeitung - US govt sends drugmakers initial offers in price talks

US govt sends drugmakers initial offers in price talks


US govt sends drugmakers initial offers in price talks
US govt sends drugmakers initial offers in price talks / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Change text size:

The move comes as President Joe Biden pushes to rein in health care costs ahead of November's election.

The negotiation program came on the back of Biden's landmark Inflation Reduction Act, a major package of energy transition policy and social reforms.

This allowed Medicare, the federal health insurance for seniors, to start negotiating drug costs -- a first in its nearly 60-year existence.

"This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set," the White House said in a statement on Thursday.

It did not reveal how much it offered for each drug.

A Johnson & Johnson spokesperson told AFP the company has received an initial price from the government but said it was "respecting the confidential nature of the process."

Last October, major drugmakers behind 10 selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.

But pharmaceutical companies have pushed back against the initiative, earlier saying that they came on board as they had no choice.

While the US government is initially limited to picking 10 drugs for price talks, it can expand the program in subsequent years.

The drugs include Farxiga by AstraZeneca used against diabetes, Entresto by Novartis to treat heart failure, as well as anticoagulant Eliquis -- used by millions of Medicare beneficiaries.

According to the White House, nine million seniors on Medicare were prescribed the 10 drugs in 2022, spending some $3.4 billion out-of-pocket that year.

The statement also took aim at Big Pharma, which the White House said "charged Americans two to three times more" than in other countries, even when accounting for rebates and discounts.

Biden, who is campaigning for reelection with a large focus on easing voters' financial burdens, said in a separate statement: "My Administration won't stop fighting to lower health care costs for seniors and families."

New negotiated prices for the 10 prescription drugs are set to be announced later this year.

Medicare is expected to negotiate prices for up to 60 drugs over the next four years, and up to an additional 20 drugs each year after that.

Several companies have taken legal action challenging the provisions.

(M.Travkina--DTZ)

Featured

RCSI President Calls for Enhanced Surgical Research Support at Millin Meeting

Professor Michael Kerin, president of the Royal College of Surgeons in Ireland (RCSI), has called for increased support for surgeons to strengthen the nation's surgical research capacity. His remarks preceded the annual Millin Meeting, a gathering of leading healthcare experts focused on integrating innovation and clinical trials into everyday surgical practice.

Toddler Diagnosed With Leukemia After Symptoms Dismissed as Winter Illness

Manraj Singh Hans, now seven, was diagnosed with acute lymphoblastic leukemia in February 2023 after a prolonged period during which his early symptoms were repeatedly misdiagnosed as common infections. His parents, Narinder Singh and Parm Hans, initially dismissed signs of illness as winter fatigue before blood in the child’s diaper prompted urgent medical intervention.

American Airlines passenger falls ill and vomits on three travellers

A passenger on board an American Airlines reportedly experienced a medical episode mid-flight A morning flight from Philadelphia to Miami was thrown into disarray after a passenger reportedly vomited over three other travellers.

iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury

Researchers at Keiō University are leveraging induced pluripotent stem (iPS) cells to accelerate drug discovery for rare neurological conditions. Director Okano Hideyuki reports that human-derived cell models have enabled the rapid identification of potential treatments for amyotrophic lateral sclerosis and paved the way for regenerative therapies targeting spinal cord injuries.

Change text size: